


# Author's Accepted Manuscript

Emerging Pathways in Treating Human epidermal growth factor receptor-2-negative breast Cancer

Sotirios Stergiopoulos



[www.elsevier.com/locate/nhtm](http://www.elsevier.com/locate/nhtm)

PII: S2307-5023(14)00076-9  
DOI: <http://dx.doi.org/10.1016/j.nhtm.2014.11.059>  
Reference: NHTM11

To appear in: *New Horizons in Translational Medicine*

Cite this article as: Sotirios Stergiopoulos, Emerging Pathways in Treating Human epidermal growth factor receptor-2-negative breast Cancer, *New Horizons in Translational Medicine*, <http://dx.doi.org/10.1016/j.nhtm.2014.11.059>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Emerging Pathways in Treating Human Epidermal Growth Factor Receptor-2-Negative  
Breast Cancer**

Sotirios Stergiopoulos

Celgene Corporation, Berkeley Heights, NJ, USA

**Running Title:** Emerging Treatments in HER-2-Negative Breast Cancer

**Article type:** review

**Corresponding Author:**

Sotirios G. Stergiopoulos, MD

Celgene Corporation

86 Morris Avenue, H233C

Summit, NJ, USA

**Phone:** (908) 673-9285

**Email:** sstergiopoulos@celgene.com

**Source(s) of support (in the form of grants, equipment, drugs, or all of these):**

The author is employed by Celgene Corporation and received editorial support that was funded by Celgene Corporation.

Download English Version:

<https://daneshyari.com/en/article/3815606>

Download Persian Version:

<https://daneshyari.com/article/3815606>

[Daneshyari.com](https://daneshyari.com)